東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

PET Theranostics for Molecular Imagi...

University of Toronto (Canada)., Pharmaceutical Sciences.

Linked to FindBook

Google Book

Amazon

博客來

PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer.

Record Type:	Electronic resources : Monograph/item
Title/Author:	PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer./
Author:	Boyle, Amanda Jean.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	188 p.
Notes:	Source: Dissertations Abstracts International, Volume: 81-02, Section: B.
Contained By:	Dissertations Abstracts International81-02B.
Subject:	Pharmaceutical sciences. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13426660
ISBN:	9781085584203

PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer.
Boyle, Amanda Jean.

PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 188 p.

Source: Dissertations Abstracts International, Volume: 81-02, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2019.

This item must not be sold to any third party vendors.

Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of pancreatic cancer tumours. Panitumumab is an antibody that targets EGFR and can be radiolabeled for molecular imaging and radioimmunotherapy (RIT). This thesis aimed to develop a "theranostic" agent that could be used for both imaging and treatment of pancreatic tumours. The first study demonstrated the ability of 64Cu-panitumumab F(ab')2 fragments to visualize patient-derived orthotopic pancreatic cancer xenograft mouse models with PET/CT imaging and showed the superiority of panitumumab F(abʹ)2 over IgG or Fab fragments. Next, studies were performed involving metal-chelating polymers (MCPs) to allow antibodies to carry up to 20-fold more chelation sites compared to antibodies directly derivatized with chelators for 64Cu-radiolabeling, thereby amplifying radiation delivered per antibody. This work demonstrated that the presence of pendant PEG chains on MCPs resulted in longer blood circulation times compared to MCPs without pendant PEG chains. The next study demonstrated that 64Cu-panitumumab F(ab')2 was useful in RIT when combined with radiosensitizing agents in pancreatic cancer xenograft mouse models. Tumour regression was not achieved so the final investigation compared 64Cu and 177Lu-panitumumab F(abʹ)2, which have similar β-emission energies but 177Lu has double the abundance of β-emissions compared to 64Cu. 64Cu-RIT and 177Lu-RIT were compared to external γ-irradiation to determine their relative biological effectiveness (RBE) in four pancreatic cancer cell lines, with different EGFR overexpression and proliferation rates. This work demonstrated that the degree of EGFR overexpression did not predict responsiveness of cells to RIT with 64Cu- or 177Lu-RIT. Also, fast growing cells responded very well to 64Cu-RIT while slow growing cells responded extremely poorly, while proliferation rate did not correlate with response to 177Lu-RIT. In conclusion, 64Cu-panitumumab F(ab')2 fragments can be useful in PET imaging of pancreatic cancer tumours and that 177Lu-panitumumab F(ab')2 fragments are more appropriate for RIT.

ISBN: 9781085584203Subjects--Topical Terms:

3173021
Pharmaceutical sciences.
Subjects--Index Terms:

Cellular dosimetry

PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer.
LDR:03258nmm a2200349 4500 001 2272355
005 20201105110029.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781085584203
035 $a (MiAaPQ)AAI13426660
035 $a AAI13426660
040 $a MiAaPQ $c MiAaPQ
100 1 $a Boyle, Amanda Jean. $3 3549789
245 1 0 $a PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 188 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-02, Section: B.
500 $a Advisor: Reilly, Raymond M.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of pancreatic cancer tumours. Panitumumab is an antibody that targets EGFR and can be radiolabeled for molecular imaging and radioimmunotherapy (RIT). This thesis aimed to develop a "theranostic" agent that could be used for both imaging and treatment of pancreatic tumours. The first study demonstrated the ability of 64Cu-panitumumab F(ab')2 fragments to visualize patient-derived orthotopic pancreatic cancer xenograft mouse models with PET/CT imaging and showed the superiority of panitumumab F(abʹ)2 over IgG or Fab fragments. Next, studies were performed involving metal-chelating polymers (MCPs) to allow antibodies to carry up to 20-fold more chelation sites compared to antibodies directly derivatized with chelators for 64Cu-radiolabeling, thereby amplifying radiation delivered per antibody. This work demonstrated that the presence of pendant PEG chains on MCPs resulted in longer blood circulation times compared to MCPs without pendant PEG chains. The next study demonstrated that 64Cu-panitumumab F(ab')2 was useful in RIT when combined with radiosensitizing agents in pancreatic cancer xenograft mouse models. Tumour regression was not achieved so the final investigation compared 64Cu and 177Lu-panitumumab F(abʹ)2, which have similar β-emission energies but 177Lu has double the abundance of β-emissions compared to 64Cu. 64Cu-RIT and 177Lu-RIT were compared to external γ-irradiation to determine their relative biological effectiveness (RBE) in four pancreatic cancer cell lines, with different EGFR overexpression and proliferation rates. This work demonstrated that the degree of EGFR overexpression did not predict responsiveness of cells to RIT with 64Cu- or 177Lu-RIT. Also, fast growing cells responded very well to 64Cu-RIT while slow growing cells responded extremely poorly, while proliferation rate did not correlate with response to 177Lu-RIT. In conclusion, 64Cu-panitumumab F(ab')2 fragments can be useful in PET imaging of pancreatic cancer tumours and that 177Lu-panitumumab F(ab')2 fragments are more appropriate for RIT.
590 $a School code: 0779.
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Cellular dosimetry
653 $a EGFR
653 $a Pancreatic cancer
653 $a Panitumumab
653 $a Radioimmunotherapy
690 $a 0572
710 2 $a University of Toronto (Canada). $b Pharmaceutical Sciences. $3 3170825
773 0 $t Dissertations Abstracts International $g 81-02B.
790 $a 0779
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13426660